Evidence Grade C — Moderate human evidence. 24 published studies, 17 human. 84 registered clinical trials.
Medically reviewed by a licensed medical professional
Lypressin (lysine vasopressin) is a synthetic version of the natural pig form of vasopressin. It was previously sold as a nasal spray (Diapid) for diabetes insipidus but was voluntarily withdrawn from the market around 1997 — not for safety reasons, but because desmopressin offered a clearly better clinical profile with longer duration and fewer side effects.
Lypressin is also known by these brand and alternate names:
24 published studies: 17 human, 5 animal, 1 in-vitro, 4 reviews
Lypressin was previously marketed as Diapid (Sandoz) nasal spray for diabetes insipidus. It was voluntarily withdrawn from the market around 1997, not for safety or efficacy reasons, but because desmopressin offered a superior clinical profile: longer duration of action, greater selectivity for kidney receptors, minimal blood pressure effects, and multiple formulation options.
Lypressin is of historical interest as an early synthetic hormone replacement but has no current clinical role.
Lypressin acts on the same vasopressin receptors as the human hormone, promoting water reabsorption in the kidneys. It differs from human vasopressin at a single amino acid position (lysine instead of arginine at position 8). Its short duration of action (3–4 hours) and non-selective receptor profile — causing blood vessel constriction alongside the desired kidney effects — made it clinically inferior to desmopressin.
Lypressin is of historical interest only. Its short duration of action (3-4 hours) and non-selective receptor profile — causing blood vessel constriction alongside the desired kidney effects — made it clinically inferior to desmopressin in every meaningful way. No current clinical role exists. It retains minor relevance as a pharmacological research tool for studying vasopressin receptor subtypes. No active development programmes exist.
PeptideTrace tracks 84 registered clinical trials for Lypressin sourced from ClinicalTrials.gov.
Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury
Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation
Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock
Lypressin (lysine vasopressin) is a synthetic nonapeptide (9 AA: Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2), MW 1,056.2 Da. Natural porcine vasopressin, differing from human AVP by Lys8 vs. Arg8. Disulfide bridge Cys1-Cys6, C-terminal glycinamide. Previously marketed as Diapid nasal spray; withdrawn ~1997 when desmopressin became preferred. Half-life ~10-20 minutes.
Research suggests activity via V2 receptors on renal collecting duct: Gs/cAMP/PKA pathway phosphorylates AQP2, increasing water permeability and enabling concentrated urine. Also V1a on vascular smooth muscle (vasoconstriction via Gq/PLC/Ca2+) and V1b on pituitary (ACTH secretion). Shorter half-life and dual V1/V2 activity make it less selective than desmopressin.
Previously marketed as Diapid (Sandoz). Voluntarily withdrawn ~1997 (not for safety/efficacy) because desmopressin offered superior properties: longer duration (6-24h vs. 3-4h), V2-selective, minimal pressor activity, multiple formulations. Historical efficacy in diabetes insipidus demonstrated but no modern Phase III trials. No longer commercially available.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Palopegteriparatide is marketed as Yorvipath (Ascendis Pharma, approved August 2024). It is the first FDA-approved PTH replacement therapy for hypoparathyroidism, a condition that previously had no approved hormone replacement and was managed only with high doses of calcium supplements and active vitamin D — an approach that does not fully normalise calcium metabolism. In the PaTHway trial, 79% of patients achieved independence from calcium and active vitamin D supplements while maintaining normal blood calcium levels, compared to 5% on placebo. This represents a fundamental shift in managing hypoparathyroidism — from supplementation to actual hormone replacement. Patients also showed improvements in kidney function markers and bone metabolism parameters.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
